Data published in Hematological Oncology suggested that hypercalcemia at diffuse large B-cell lymphoma (DLBCL) diagnosis is strongly correlated with adverse prognostic factors and a short diagnosis-to-treatment interval.
Moreover, the adverse impact of hypercalcemia on outcome appears to be closely linked to International Prognostic Index (IPI) parameters, indicating that hypercalcemia is a biomarker of the underlying biological aggressiveness of DLBCL.
“Although hypercalcemia is a known complication of DLBCL, limited data are available concerning its prevalence and its clinical and prognosis significant in this setting,” the authors wrote. “The aims of the present retrospective study, were, first, to investigate the prevalence of hypercalcemia at diagnosis of de novo DLBCL compared to transformed indolent lymphomas and, second, to explore its clinical significance and…
